CDH1 and cancer: In BCs, a molecular signature including several EMT markers (e.g., CK5/6, CK8/18, E-cadherin, and P-cadherin) was associated with metastatic progression and successfully used to group cancer patients in poor- or good-prognosis clusters [101].